Not all Alzheimer’s damage is the same

(Credit: neilconway/Flickr)

Researchers have discovered that Alzheimer’s disease damages different types of brain cells depending on the genes involved.

Alzheimer’s disease implicates multiple genes. Some are linked to early-onset Alzheimer’s, a condition that develops in one’s 30s, 40s, and 50s, while others are associated with the more common late-onset form of the disease.

Eventually, all Alzheimer’s patients develop dementia, and their brain cells die. But not all genes linked to the disease contribute to damage in the same way, and understanding the various ways specific genes lead to damage is important to developing potential treatments to prevent or halt Alzheimer’s.

“Different genes contribute to Alzheimer’s damage in different ways, and we are working to identify therapeutic targets to prevent that damage,” says senior investigator Carlos Cruchaga, associate professor of psychiatry at the Washington University School of Medicine in St. Louis. “Alzheimer’s always leads to neuronal death, but we might identify better targets for therapy if we know how various genes lead to damage.”

Listen to Cruchaga explain the findings:

The researchers analyzed brain samples from deceased patients with rare and common forms of Alzheimer’s. The tissue banks also included samples from people who did not have the disorder.

As expected, the brains of Alzheimer’s patients generally contained fewer neurons and larger numbers of brain cells called astrocytes. But a closer look showed that the cellular “signatures” in the brains sometimes differed, depending on the genes contributing to the disease.

“Our computer method determined the proportions of each cell type—neurons, astrocytes, oligodendrocytes, microglial cells—and found that specific gene variants were linked to different proportions of these cell types,” says co-investigator Oscar Harari, assistant professor of psychiatry.

Using a computerized method, the researchers attempted to differentiate the effects of the genes and identify pathways that might be therapeutic targets.

Harari, Cruchaga, and their colleagues analyzed postmortem samples from the Mayo Clinic Brain Bank, the Mount Sinai Brain Bank, and from the Knight Alzheimer’s Disease Research Center at Washington University, as well as from deceased participants in the Dominantly Inherited Alzheimer Network (DIAN) Observational Study of people with genetic mutations that led to early-onset Alzheimer’s.

Mutations in the genes APP, PSEN1, and PSEN2 are known to cause inherited Alzheimer’s. Samples from such patients showed lower numbers of neurons and higher numbers of astrocytes than samples from people who had Alzheimer’s but did not carry mutations in any of those genes.

The researchers found similar patterns of more astrocytes and fewer neurons in patients with APOE4, a gene known to increase the risk of late-onset Alzheimer’s. But in carriers of a gene variant called TREM2, neuronal loss was not as pronounced. Instead, the TREM2 mutation damaged glial cells in the brain.

“Many efforts are underway to identify novel Alzheimer’s disease genes,” Cruchaga says. “But once a gene is identified, we need to know what it does in the brain to understand how it can lead to disease. We also need to account for the proportions of various types of cells if we want to know what we should target with therapies.”

What if Alzheimer’s comes from axon ‘transport’ not amyloids?

Using computerized methods to identify types of brain cells in tissue samples from deceased patients, the researchers found that populations of various brain cell types are different, depending on which genes led to the development of Alzheimer’s.

The research appears in the journal Genome Medicine.

The National Institute on Aging, the National Institute of Neurological Disorders and Stroke, and the National Institute of Mental Health at the National Institutes of Health funded the research. Please consult the paper for a full list of grants funding the brain banks that provided tissue samples to the researchers involved in this study.

The Alzheimer’s Association, the American Federation for Aging Research, the BrightFocus Foundation, the Tau Consortium, and the Brain and Behavior Research Foundation provided additional funding.

Source: Washington University in St. Louis